Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Raw Materials: 2023-2024

Historic Raw Materials for Ligand Pharmaceuticals (LGND) over the last 2 years, with Dec 2024 value amounting to $603,000.

  • Ligand Pharmaceuticals' Raw Materials rose 43.57% to $603,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $603,000, marking a year-over-year increase of 43.57%. This contributed to the annual value of $603,000 for FY2024, which is 43.57% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Raw Materials of $603,000 as of FY2024, which was up 43.57% from $420,000 recorded in FY2023.
  • Ligand Pharmaceuticals' Raw Materials' 5-year high stood at $603,000 during FY2024, with a 5-year trough of $420,000 in FY2023.
  • Over the past 2 years, Ligand Pharmaceuticals' median Raw Materials value was $511,500 (recorded in 2023), while the average stood at $511,500.
  • Data for Ligand Pharmaceuticals' Raw Materials shows a peak YoY surged of 43.57% (in 2024) over the last 5 years.
  • Ligand Pharmaceuticals' Raw Materials (Yearly) stood at $420,000 in 2023, then soared by 43.57% to $603,000 in 2024.